{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:28:15Z","timestamp":1775842095036,"version":"3.50.1"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023673","name":"Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002713","name":"Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.prp.2025.156234","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T12:37:13Z","timestamp":1758026233000},"page":"156234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Taming hyper-active Cdk5: Disrupting the Cdk5\u2013p25 axis as a therapeutic avenue for neurodegeneration and beyond"],"prefix":"10.1016","volume":"275","author":[{"given":"Emadeldin M.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulaiman A.","family":"Alsalamah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally Mostafa","family":"Khadrawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-0933","authenticated-orcid":false,"given":"Noha A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faris F. Aba","family":"Alkhayl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al Mokhtar","family":"Lamsabhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.prp.2025.156234_bib1","doi-asserted-by":"crossref","first-page":"7287","DOI":"10.1007\/s12035-024-04047-1","article-title":"Cyclin-dependent kinase 5 and neurodegenerative diseases","volume":"61","author":"Song","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12929-021-00774-y","article-title":"Three decades of Cdk5","volume":"28","author":"Pao","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"24","key":"10.1016\/j.prp.2025.156234_bib3","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1091\/mbc.E15-06-0415","article-title":"Peptide TFP5\/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson\u2019s disease","volume":"26","author":"Binukumar","year":"2015","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.prp.2025.156234_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120986","article-title":"Cdk5-p25 as a key element linking amyloid and tau pathologies in alzheimer's disease: mechanisms and possible therapeutic interventions","volume":"308","author":"Maitra","year":"2022","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.prp.2025.156234_bib5","article-title":"Dendritic distribution of CDK5 mRNA and p35 mRNA, and a glutamate-responsive increase of CDK5\/p25 complex contribute to tau hyperphosphorylation","volume":"1866","author":"Tanaka","year":"2022","journal-title":"Biochim. Et. Biophys. Acta (BBA) Gen. Subj."},{"key":"10.1016\/j.prp.2025.156234_bib6","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fnmol.2022.1030639","article-title":"Focusing on cyclin-dependent kinases 5: a potential target for neurological disorders","volume":"15","author":"Tian","year":"2022","journal-title":"Front. Mol. Neurosci."},{"issue":"5","key":"10.1016\/j.prp.2025.156234_bib7","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1007\/s12035-023-03783-0","article-title":"Unveiling potential neurotoxic mechansisms: Pb-Induced activation of CDK5-p25 signaling axis in Alzheimer\u2019s disease development, emphasizing CDK5 inhibition and formation of toxic p25 species","volume":"61","author":"Lokesh","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.prp.2025.156234_bib8","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3390\/cells10051236","article-title":"Insulin resistance and diabetes mellitus in Alzheimer\u2019s disease","volume":"10","author":"Burillo","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2337\/db16-1587","article-title":"Inhibition of Cdk5 promotes \u03b2-Cell differentiation from ductal progenitors","volume":"67","author":"Liu","year":"2017","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.prp.2025.156234_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166986","article-title":"Cdk5-mediated oligodendrocyte myelin breakdown and neuroinflammation: implications for the link between type 2 diabetes and alzheimer's disease","volume":"1870","author":"Paul","year":"2024","journal-title":"Biochim. Et. Biophys. Acta (BBA) Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11033-025-10253-4","article-title":"CDK5: insights into its roles in diseases","volume":"52","author":"Wang","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"1-3","key":"10.1016\/j.prp.2025.156234_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0014-5793(02)02934-4","article-title":"A survey of Cdk5 activator p35 and p25 levels in alzheimer's disease brains","volume":"523","author":"Tseng","year":"2002","journal-title":"FEBS Lett."},{"issue":"6839","key":"10.1016\/j.prp.2025.156234_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/35081149","article-title":"p25 protein in neurodegeneration","volume":"411","author":"Patrick","year":"2001","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.prp.2025.156234_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jnc.13620","article-title":"Involvement of aberrant cyclin-dependent kinase 5\/p25 activity in experimental traumatic brain injury","volume":"138","author":"Yousuf","year":"2016","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JAD-160916","article-title":"TFP5, a peptide inhibitor of aberrant and hyperactive Cdk5\/p25, attenuates pathological phenotypes and restores synaptic function in CK-p25Tg mice","volume":"56","author":"Shukla","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.emboj.7600441","article-title":"A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons","volume":"24","author":"Zheng","year":"2005","journal-title":"EMBO J."},{"issue":"16","key":"10.1016\/j.prp.2025.156234_bib17","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217864120","article-title":"A Cdk5-derived peptide inhibits Cdk5\/p25 activity and improves neurodegenerative phenotypes","volume":"120","author":"Pao","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.prp.2025.156234_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063332","article-title":"Cdk5 inhibitory peptide (CIP) inhibits Cdk5\/p25 activity induced by high glucose in pancreatic beta cells and recovers insulin secretion from p25 damage","volume":"8","author":"Zheng","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41398-024-03084-7","article-title":"P-tau217 and other blood biomarkers of dementia: variation with time of day","volume":"14","author":"della Monica","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-024-01655-w","article-title":"Plasma phospho-tau217 as a predictive biomarker for alzheimer's disease in a large south American cohort","volume":"17","author":"Pandey","year":"2025","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41398-025-03551-9","article-title":"CDK5-mediated hyperphosphorylation of Tau217 impairs neuronal synaptic structure and exacerbates cognitive impairment in alzheimer's disease","volume":"15","author":"Fu","year":"2025","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.prp.2025.156234_bib22","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/acschemneuro.0c00096","article-title":"Physiological and pathological roles of Cdk5: potential directions for therapeutic targeting in neurodegenerative disease","volume":"11","author":"Allnutt","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12943-023-01895-8","article-title":"CDK5: an oncogene or an anti-oncogene: location location location","volume":"22","author":"Nikhil","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12929-021-00774-y","article-title":"Three decades of Cdk5","volume":"28","author":"Pao","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"9","key":"10.1016\/j.prp.2025.156234_bib25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.4161\/epi.21568","article-title":"An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function","volume":"7","author":"Kar","year":"2012","journal-title":"Epigenetics"},{"issue":"9","key":"10.1016\/j.prp.2025.156234_bib26","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/s41418-023-01196-z","article-title":"Cyclers\u2019 kinases in cell division: from molecules to cancer therapy","volume":"30","author":"Milletti","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.prp.2025.156234_bib27","article-title":"Universit\u00e9 d\u2032Ottawa\/University of Ottawa","author":"Iyirhiaro","year":"2013","journal-title":"Role Cell Cycle Mach. Ischemic Neuron Death"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s43556-021-00029-0","article-title":"Post-translational modifications of CDK5 and their biological roles in cancer","volume":"2","author":"Gao","year":"2021","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70145","article-title":"The role of acetylation and deacetylation in cancer metabolism","volume":"15","author":"Wang","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"22","key":"10.1016\/j.prp.2025.156234_bib30","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.2174\/13816128113196660745","article-title":"Regulation of eNOS enzyme activity by posttranslational modification","volume":"20","author":"Heiss, E","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"26","key":"10.1016\/j.prp.2025.156234_bib31","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1021\/bi100631f","article-title":"Membrane association facilitates degradation and cleavage of the Cyclin-Dependent kinase 5 activators p35 and p39","volume":"49","author":"Minegishi","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.prp.2025.156234_bib32","series-title":"Elucidating the unknown role of cyclin dependent kinase 5 in cardiac pathophysiological conditions","author":"Aina-Badejo","year":"2021"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib33","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1038\/ncomms5826","article-title":"Cdk5-mediated phosphorylation of RapGEF2 controls neuronal migration in the developing cerebral cortex","volume":"5","author":"Ye","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2025.156234_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mcn.2012.08.005","article-title":"Differential roles of cyclin-dependent kinase 5 in tangential and radial migration of cerebellar granule cells","volume":"52","author":"Umeshima","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.prp.2025.156234_bib35","article-title":"And Reward-Related behavior","author":"Benavides","year":"2010","journal-title":"Role Cdk5 Regul. Dopamine Neurotransmission Neuron Excit."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13041-022-00939-2","article-title":"Downregulation of CDK5 signaling in the dorsal striatum alters striatal microcircuits implicating the association of pathologies with circadian behavior in mice","volume":"15","author":"Zhou","year":"2022","journal-title":"Mol. Brain"},{"issue":"7305","key":"10.1016\/j.prp.2025.156234_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"issue":"7305","key":"10.1016\/j.prp.2025.156234_bib38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib39","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1038\/s41598-023-29322-4","article-title":"Cdk5 mediates rotational force-induced brain injury","volume":"13","author":"Umfress","year":"2023","journal-title":"Sci. Rep."},{"issue":"31","key":"10.1016\/j.prp.2025.156234_bib40","doi-asserted-by":"crossref","first-page":"10415","DOI":"10.1523\/JNEUROSCI.0710-14.2014","article-title":"Cyclin-Dependent kinase 5 mediates adult OPC maturation and myelin repair through modulation of akt and GsK-3\u03b2 signaling","volume":"34","author":"Luo","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.prp.2025.156234_bib41","article-title":"The university of arizona","author":"Boinon","year":"2022","journal-title":"Deciphering Funct. Collapsin Response Mediat. Protein 2 (CRMP2) Nociceptive Spinal Neurotransmission"},{"issue":"3","key":"10.1016\/j.prp.2025.156234_bib42","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1471-4159.2011.07222.x","article-title":"Calpastatin, an endogenous calpain-inhibitor protein, regulates the cleavage of the Cdk5 activator p35 to p25","volume":"117","author":"Sato","year":"2011","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.prp.2025.156234_bib43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1097-2765(01)00343-4","article-title":"Structure and regulation of the CDK5-p25nck5a complex","volume":"8","author":"Tarricone","year":"2001","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.prp.2025.156234_bib44","doi-asserted-by":"crossref","first-page":"17373","DOI":"10.18632\/oncotarget.14538","article-title":"Biological functions of CDK5 and potential CDK5 targeted clinical treatments","volume":"8","author":"Shupp","year":"2017","journal-title":"Oncotarget"},{"issue":"39","key":"10.1016\/j.prp.2025.156234_bib45","doi-asserted-by":"crossref","first-page":"eabo4662","DOI":"10.1126\/sciadv.abo4662","article-title":"Neurons burdened by DNA double-strand breaks incite microglia activation through antiviral-like signaling in neurodegeneration","volume":"8","author":"Welch","year":"2022","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.prp.2025.156234_bib46","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1523\/JNEUROSCI.5177-11.2012","article-title":"Cdk5\/p25-Induced cytosolic PLA2-Mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration","volume":"32","author":"Sundaram","year":"2012","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.prp.2025.156234_bib47","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.prp.2025.156234_bib48","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jmb.2010.06.040","article-title":"Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP","volume":"401","author":"Cardone","year":"2010","journal-title":"J. Mol. Biol."},{"issue":"11","key":"10.1016\/j.prp.2025.156234_bib49","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1074\/jbc.M509699200","article-title":"Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5\/p25 and CDK2\/cyclin a dynamics","volume":"281","author":"Otyepka","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.prp.2025.156234_bib50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(00)80351-7","article-title":"Activation mechanism of the MAP kinase ERK2 by dual phosphorylation","volume":"90","author":"Canagarajah","year":"1997","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib51","doi-asserted-by":"crossref","first-page":"13676","DOI":"10.1038\/s41598-018-31785-9","article-title":"The acetylation of cyclin-dependent kinase 5 at lysine 33 regulates kinase activity and neurite length in hippocampal neurons","volume":"8","author":"Lee","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.prp.2025.156234_bib52","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1021\/acs.jmedchem.1c02069","article-title":"Discovery and optimization of highly selective inhibitors of CDK5","volume":"65","author":"Daniels","year":"2022","journal-title":"J. Med Chem."},{"issue":"23","key":"10.1016\/j.prp.2025.156234_bib53","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1073\/pnas.2232515100","article-title":"Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of parkinson's disease","volume":"100","author":"Smith","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.prp.2025.156234_bib54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1097-2765(01)00343-4","article-title":"Structure and regulation of the CDK5-p25(nck5a) complex","volume":"8","author":"Tarricone","year":"2001","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib55","doi-asserted-by":"crossref","first-page":"10165","DOI":"10.1038\/s41467-024-54500-x","article-title":"Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity","volume":"15","author":"Mabanglo","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2025.156234_bib56","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.prp.2025.156234_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118085","article-title":"Novel dual-targeting PROTAC degraders of GSK-3\u03b2 and CDK5: a promising approach for pancreatic cancer treatment","volume":"120","author":"Neerasa","year":"2025","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.prp.2025.156234_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176760","article-title":"CDK5 as a therapeutic tool for the treatment of alzheimer's disease: a review","volume":"978","author":"Garemilla","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.prp.2025.156234_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1039\/D2CB00201A","article-title":"Emerging approaches to CDK inhibitor development, a structural perspective","volume":"4","author":"Hope","year":"2023","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.prp.2025.156234_bib60","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fncel.2023.1106176","article-title":"APPs\u03b1 rescues CDK5 and GSK3\u03b2 dysregulation and restores normal spine density in tau transgenic mice","volume":"17","author":"Baltissen","year":"2023","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.prp.2025.156234_bib61","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1021\/acs.jmedchem.1c02069","article-title":"Discovery and optimization of highly selective inhibitors of CDK5","volume":"65","author":"Daniels","year":"2022","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.prp.2025.156234_bib62","doi-asserted-by":"crossref","first-page":"11733","DOI":"10.3390\/ijms241411733","article-title":"TP5: a novel therapeutic approach targeting aberrant and hyperactive CDK5\/p25 for the treatment of colorectal carcinoma","volume":"24","author":"Amin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156234_bib63","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fphar.2022.863762","article-title":"Systemic administration of a brain permeable Cdk5 inhibitor alters neurobehavior","volume":"13","author":"Umfress","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2025.156234_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118085","article-title":"Novel dual-targeting PROTAC degraders of GSK-3\u03b2 and CDK5: a promising approach for pancreatic cancer treatment","volume":"120","author":"Neerasa","year":"2025","journal-title":"Bioorg. Med. Chem."},{"issue":"6762","key":"10.1016\/j.prp.2025.156234_bib65","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/45159","article-title":"Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration","volume":"402","author":"Patrick","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JAD-160916","article-title":"TFP5, a peptide inhibitor of aberrant and hyperactive Cdk5\/p25, attenuates pathological phenotypes and restores synaptic function in CK-p25Tg mice","volume":"56","author":"Shukla","year":"2017","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.prp.2025.156234_bib67","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3389\/fnagi.2018.00162","article-title":"Cdk5 inhibitory peptide prevents loss of dopaminergic neurons and alleviates behavioral changes in an MPTP induced Parkinson\u2019s disease mouse model","volume":"10","author":"He","year":"2018","journal-title":"Front. Aging Neurosci."},{"issue":"9","key":"10.1016\/j.prp.2025.156234_bib68","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1007\/s12035-024-04003-z","article-title":"Therapeutic potential effect of glycogen synthase kinase 3 beta (GSK-3\u03b2) inhibitors in parkinson disease: exploring an overlooked avenue","volume":"61","author":"Turkistani","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.prp.2025.156234_bib69","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.18632\/oncotarget.23749","article-title":"Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy","volume":"9","author":"Robb","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.prp.2025.156234_bib70","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/cancers12071935","article-title":"TP5, a peptide inhibitor of aberrant and hyperactive CDK5\/p25: a novel therapeutic approach against glioblastoma","volume":"12","author":"Tabouret","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.prp.2025.156234_bib71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tranon.2015.06.002","article-title":"Cyclin-Dependent kinase 5 (CDK5) controls melanoma cell motility, invasiveness, and metastatic Spread\u2014Identification of a promising novel therapeutic target","volume":"8","author":"Bisht","year":"2015","journal-title":"Transl. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.156234_bib72","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/21541264.2018.1539615","article-title":"Therapeutic targeting of transcriptional cyclin-dependent kinases","volume":"10","author":"Galbraith","year":"2019","journal-title":"Transcription"},{"issue":"21","key":"10.1016\/j.prp.2025.156234_bib73","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.3390\/cancers13215506","article-title":"Inhibitors, PROTACs and molecular glues as diverse therapeutic modalities to target Cyclin-Dependent kinase","volume":"13","author":"Rana","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.prp.2025.156234_bib74","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1039\/D3SC05937E","article-title":"High-throughput drug target discovery using a fully automated proteomics sample preparation platform","volume":"15","author":"Wu","year":"2024","journal-title":"Chem. Sci."},{"issue":"6","key":"10.1016\/j.prp.2025.156234_bib75","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3390\/ijms22062806","article-title":"Inhibitors of Cyclin-Dependent kinases: types and their mechanism of action","volume":"22","author":"\u0141ukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156234_bib76","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2019.01.003","article-title":"Recent development of CDK inhibitors: an overview of CDK\/inhibitor co-crystal structures","volume":"164","author":"Cheng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.prp.2025.156234_bib77","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/9781394270576.ch9","article-title":"Antioxidants against neurological disorders","author":"Narang","year":"2025","journal-title":"Antioxidants"},{"issue":"7","key":"10.1016\/j.prp.2025.156234_bib78","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.bmcl.2010.01.132","article-title":"Design of potent and selective GSK3\u03b2 inhibitors with acceptable safety profile and pharmacokinetics","volume":"20","author":"Lesuisse","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.prp.2025.156234_bib79","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1021\/acs.jmedchem.3c00566","article-title":"Novel medicinal chemistry strategies targeting CDK5 for drug discovery","volume":"66","author":"Tang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.prp.2025.156234_bib80","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41434-021-00244-y","article-title":"Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9","volume":"29","author":"Chatterjee","year":"2022","journal-title":"Gene Ther."},{"issue":"6784","key":"10.1016\/j.prp.2025.156234_bib81","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/35012636","article-title":"Neurotoxicity induces cleavage of p35 to p25 by calpain","volume":"405","author":"Lee","year":"2000","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.prp.2025.156234_bib82","doi-asserted-by":"crossref","first-page":"12841","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156234_bib83","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fcell.2021.766773","article-title":"Human induced pluripotent stem cell models of frontotemporal dementia with tau pathology","volume":"9","author":"K\u00fchn","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.prp.2025.156234_bib84","first-page":"2020","article-title":"A cyclin-dependent kinase 5-derived peptide inhibits Cdk5\/p25 activity and improves neurodegenerative phenotypes","author":"Seo","year":"2020","journal-title":"bioRxiv"},{"issue":"8","key":"10.1016\/j.prp.2025.156234_bib85","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/jnr.23576","article-title":"Cyclin-Dependent kinase 5 targeting prevents \u03b2-Amyloid aggregation involving glycogen synthase kinase 3\u03b2 and phosphatases","volume":"93","author":"Castro-Alvarez","year":"2015","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib86","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","article-title":"Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases","volume":"19","author":"Holm","year":"2022","journal-title":"RNA Biol."},{"issue":"19","key":"10.1016\/j.prp.2025.156234_bib87","doi-asserted-by":"crossref","first-page":"14865","DOI":"10.3390\/ijms241914865","article-title":"CRISPR\/dCas9 tools: epigenetic mechanism and application in gene transcriptional regulation","volume":"24","author":"Cai","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2025.156234_bib88","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/cells12050730","article-title":"CRISPR\/dCas9-KRAB-Mediated suppression of S100b restores p53-Mediated apoptosis in melanoma cells","volume":"12","author":"Roy Choudhury","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib89","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1038\/s41598-020-68257-y","article-title":"Transcriptional repression of PTEN in neural cells using CRISPR\/dCas9 epigenetic editing","volume":"10","author":"Moses","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2025.156234_bib90","series-title":"The neurodegeneration revolution: emerging therapies and sustainable solutions","author":"Koduru","year":"2024"},{"issue":"2","key":"10.1016\/j.prp.2025.156234_bib91","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3233\/JAD-190099","article-title":"AAV9-Mediated Cdk5 inhibitory peptide reduces hyperphosphorylated tau and inflammation and ameliorates behavioral changes caused by overexpression of p25 in the brain","volume":"70","author":"Xu","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers7010179","article-title":"Targeting Cyclin-Dependent kinases in human cancers: from small molecules to peptide inhibitors","volume":"7","author":"Peyressatre","year":"2015","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.prp.2025.156234_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050063","article-title":"Cdk5 is involved in BDNF-Stimulated dendritic growth in hippocampal neurons","volume":"5","author":"Cheung","year":"2007","journal-title":"PLOS Biol."},{"issue":"11","key":"10.1016\/j.prp.2025.156234_bib94","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.2c00523","article-title":"Peptides as pharmacological carriers to the brain: promises, shortcomings and challenges","volume":"19","author":"Parrasia","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.prp.2025.156234_bib95","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.prp.2025.156234_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.934337","article-title":"Key considerations in targeted protein degradation drug discovery and development","volume":"10","author":"Qin","year":"2022","journal-title":"Front Chem."},{"key":"10.1016\/j.prp.2025.156234_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114054","article-title":"ARN25068, a versatile starting point towards triple GSK-3\u03b2\/FYN\/DYRK1A inhibitors to tackle tau-related neurological disorders","volume":"229","author":"Demuro","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.prp.2025.156234_bib98","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0959-8049(22)01007-3","article-title":"A preclinical toxicology and pharmacology study of OQL051, a gut-restricted CDK4\/6 inhibitor for the prophylaxis of chemotherapy-induced diarrhea","volume":"174","author":"Zeng","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2025.156234_bib99","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/pharmaceutics13040500","article-title":"PLGA Nanoparticle-Based formulations to cross the Blood\u2013Brain barrier for drug delivery: from R&D to cGMP","volume":"13","author":"Zhi","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156234_bib100","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fgene.2025.1533900","article-title":"An in vivo systemic massively parallel platform for deciphering animal tissue-specific regulatory function","volume":"16","author":"Brown","year":"2025","journal-title":"Front. Genet."},{"issue":"9","key":"10.1016\/j.prp.2025.156234_bib101","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","article-title":"From structure modification to drug launch: a systematic review of the ongoing development of Cyclin-Dependent kinase inhibitors for multiple cancer therapy","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.prp.2025.156234_bib102","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0896-6273(03)00627-5","article-title":"Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles","volume":"40","author":"Cruz","year":"2003","journal-title":"Neuron"},{"issue":"21","key":"10.1016\/j.prp.2025.156234_bib103","doi-asserted-by":"crossref","first-page":"11353","DOI":"10.3390\/ijms252111353","article-title":"NF-\u03baB in Alzheimer\u2019s disease: friend or foe? Opposite functions in neurons and glial cells","volume":"25","author":"Kaltschmidt","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.prp.2025.156234_bib104","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3390\/metabo13101090","article-title":"Marine-Derived compounds for CDK5 inhibition in cancer: integrating Multi-Stage virtual screening, MM\/GBSA analysis and molecular dynamics investigations","volume":"13","author":"Shoaib","year":"2023","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.prp.2025.156234_bib105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jb\/mvad113","article-title":"Protein degraders - from thalidomide to new PROTACs","volume":"175","author":"Ito","year":"2023","journal-title":"J. Biochem."},{"issue":"16","key":"10.1016\/j.prp.2025.156234_bib106","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2025.156234_bib107","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s00204-021-03115-y","article-title":"Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling","volume":"95","author":"Verscheijden","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.prp.2025.156234_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies","volume":"32","author":"Chhabra","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.prp.2025.156234_bib109","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/db10-1048","article-title":"Cyclin-dependent kinase 5 promotes pancreatic \u03b2-cell survival via Fak-Akt signaling pathways","volume":"60","author":"Daval","year":"2011","journal-title":"Diabetes"},{"issue":"36","key":"10.1016\/j.prp.2025.156234_bib110","doi-asserted-by":"crossref","first-page":"34199","DOI":"10.1074\/jbc.M103776200","article-title":"Cyclin-dependent kinase 5 promotes insulin exocytosis *","volume":"276","author":"Lilja","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.prp.2025.156234_bib111","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1038\/srep02932","article-title":"CDK5 is essential for TGF-\u03b21-induced epithelial-mesenchymal transition and breast cancer progression","volume":"3","author":"Liang","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2025.156234_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120975","article-title":"The driving role of the Cdk5\/Tln1\/FAKS732 axis in cancer cell extravasation dissected by human vascularized microfluidic models","volume":"276","author":"Gilardi","year":"2021","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.prp.2025.156234_bib113","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1523\/JNEUROSCI.2250-15.2016","article-title":"The activators of Cyclin-Dependent kinase 5 p35 and p39 are essential for oligodendrocyte maturation, process formation, and myelination","volume":"36","author":"Luo","year":"2016","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.prp.2025.156234_bib114","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/cells12040536","article-title":"Prime editing for human gene therapy: where are we now?","volume":"12","author":"Godbout","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.prp.2025.156234_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70316","article-title":"Diagnostic performance of plasma p-tau217 and A\u03b242\/40 biomarkers in the outpatient memory clinic","volume":"21","author":"Piura","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.prp.2025.156234_bib116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.prp.2025.156234_bib117","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1299","article-title":"Cdk5-dependent regulation of glucose-stimulated insulin secretion","volume":"11","author":"Wei","year":"2005","journal-title":"Nat. Med"},{"issue":"18","key":"10.1016\/j.prp.2025.156234_bib118","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","article-title":"Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies","volume":"46","author":"Tourneau","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2025.156234_bib119","doi-asserted-by":"crossref","first-page":"46","DOI":"10.12703\/r\/10-46","article-title":"Neurofilament light: a narrative review on biomarker utility","volume":"10","author":"Narayanan","year":"2021","journal-title":"Fac. Rev."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825004273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825004273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:40:08Z","timestamp":1760503208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825004273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":119,"alternative-id":["S0344033825004273"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156234","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taming hyper-active Cdk5: Disrupting the Cdk5\u2013p25 axis as a therapeutic avenue for neurodegeneration and beyond","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156234"}}